AU2004216680B2 - Venom-derived vascular endothelial growth factor-like protein having binding activity specific to vascular endothelial growth factor receptor type 2 and use thereof - Google Patents
Venom-derived vascular endothelial growth factor-like protein having binding activity specific to vascular endothelial growth factor receptor type 2 and use thereof Download PDFInfo
- Publication number
- AU2004216680B2 AU2004216680B2 AU2004216680A AU2004216680A AU2004216680B2 AU 2004216680 B2 AU2004216680 B2 AU 2004216680B2 AU 2004216680 A AU2004216680 A AU 2004216680A AU 2004216680 A AU2004216680 A AU 2004216680A AU 2004216680 B2 AU2004216680 B2 AU 2004216680B2
- Authority
- AU
- Australia
- Prior art keywords
- protein
- vegf
- vammin
- kdr
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 407
- 102000004169 proteins and genes Human genes 0.000 title claims description 371
- 230000027455 binding Effects 0.000 title claims description 142
- 239000002435 venom Substances 0.000 title claims description 80
- 210000001048 venom Anatomy 0.000 title claims description 80
- 231100000611 venom Toxicity 0.000 title claims description 80
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title claims description 63
- 108091008605 VEGF receptors Proteins 0.000 title claims description 59
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 title claims description 27
- 230000002792 vascular Effects 0.000 title claims description 13
- 230000003511 endothelial effect Effects 0.000 title claims description 7
- 230000010005 growth-factor like effect Effects 0.000 title description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 116
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 116
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 62
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 46
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 46
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 44
- 230000001077 hypotensive effect Effects 0.000 claims description 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
- 239000000710 homodimer Substances 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 29
- 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 claims description 27
- 238000004458 analytical method Methods 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 23
- 230000002401 inhibitory effect Effects 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 150000007523 nucleic acids Chemical class 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 18
- 230000001404 mediated effect Effects 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 102000003960 Ligases Human genes 0.000 claims description 15
- 108090000364 Ligases Proteins 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 15
- 210000003494 hepatocyte Anatomy 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 13
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 13
- 230000004913 activation Effects 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 208000023589 ischemic disease Diseases 0.000 claims description 11
- 241000271033 Vipera ammodytes ammodytes Species 0.000 claims description 10
- 241001442064 Daboia russellii russellii Species 0.000 claims description 9
- 238000004587 chromatography analysis Methods 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 9
- 238000005215 recombination Methods 0.000 claims description 9
- 230000006798 recombination Effects 0.000 claims description 9
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims description 8
- 241000270295 Serpentes Species 0.000 claims description 8
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims description 8
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 8
- 230000001747 exhibiting effect Effects 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 8
- 102000004207 Neuropilin-1 Human genes 0.000 claims description 7
- 108090000772 Neuropilin-1 Proteins 0.000 claims description 7
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 claims description 7
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims description 7
- 230000001681 protective effect Effects 0.000 claims description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 6
- 230000002785 anti-thrombosis Effects 0.000 claims description 6
- 239000002220 antihypertensive agent Substances 0.000 claims description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 238000000099 in vitro assay Methods 0.000 claims description 6
- 230000002883 vasorelaxation effect Effects 0.000 claims description 6
- 230000000903 blocking effect Effects 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims description 4
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims description 4
- 238000010276 construction Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 238000003259 recombinant expression Methods 0.000 claims description 3
- 241001660838 Ammodytes Species 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 description 322
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 49
- 102000058223 human VEGFA Human genes 0.000 description 49
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 32
- 150000001413 amino acids Chemical group 0.000 description 32
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- 238000010494 dissociation reaction Methods 0.000 description 17
- 230000005593 dissociations Effects 0.000 description 17
- 238000004440 column chromatography Methods 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 125000000539 amino acid group Chemical group 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 230000033115 angiogenesis Effects 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000004872 arterial blood pressure Effects 0.000 description 11
- 230000001766 physiological effect Effects 0.000 description 10
- 239000003998 snake venom Substances 0.000 description 10
- 101000659420 Macrovipera lebetina Snake venom vascular endothelial growth factor toxin ICPP Proteins 0.000 description 9
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 9
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 238000010253 intravenous injection Methods 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 230000009870 specific binding Effects 0.000 description 9
- 208000001953 Hypotension Diseases 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000035487 diastolic blood pressure Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000035488 systolic blood pressure Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 229940126585 therapeutic drug Drugs 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 230000036543 hypotension Effects 0.000 description 5
- 210000003556 vascular endothelial cell Anatomy 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010038910 Retinitis Diseases 0.000 description 4
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 4
- 241001457745 Vipera aspis aspis Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101710118538 Protease Proteins 0.000 description 3
- 239000012614 Q-Sepharose Substances 0.000 description 3
- 239000012505 Superdex™ Substances 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000012854 evaluation process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003191 femoral vein Anatomy 0.000 description 3
- 238000001641 gel filtration chromatography Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 208000021822 hypotensive Diseases 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241000271035 Macrovipera lebetina Species 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000002965 anti-thrombogenic effect Effects 0.000 description 2
- 210000002403 aortic endothelial cell Anatomy 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 238000011158 quantitative evaluation Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 101710148026 C' protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- AVVWPBAENSWJCB-CGDLOXFJSA-N L-idofuranose Chemical compound OC[C@H](O)[C@H]1OC(O)[C@H](O)[C@H]1O AVVWPBAENSWJCB-CGDLOXFJSA-N 0.000 description 1
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 101150045515 O gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000700639 Parapoxvirus Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 241000271026 Vipera ammodytes Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000004882 diastolic arterial blood pressure Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000004873 systolic arterial blood pressure Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
- G11B7/24—Record carriers characterised by shape, structure or physical properties, or by the selection of the material
- G11B7/26—Apparatus or processes specially adapted for the manufacture of record carriers
- G11B7/266—Sputtering or spin-coating layers
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
- G11B7/24—Record carriers characterised by shape, structure or physical properties, or by the selection of the material
- G11B7/241—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material
- G11B7/242—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of recording layers
- G11B7/243—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of recording layers comprising inorganic materials only, e.g. ablative layers
- G11B7/2433—Metals or elements of Groups 13, 14, 15 or 16 of the Periodic Table, e.g. B, Si, Ge, As, Sb, Bi, Se or Te
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
- G11B7/24—Record carriers characterised by shape, structure or physical properties, or by the selection of the material
- G11B7/2403—Layers; Shape, structure or physical properties thereof
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
- G11B7/24—Record carriers characterised by shape, structure or physical properties, or by the selection of the material
- G11B7/2403—Layers; Shape, structure or physical properties thereof
- G11B7/24067—Combinations of two or more layers with specific interrelation
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
- G11B7/24—Record carriers characterised by shape, structure or physical properties, or by the selection of the material
- G11B7/241—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material
- G11B7/242—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of recording layers
- G11B7/243—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of recording layers comprising inorganic materials only, e.g. ablative layers
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
- G11B7/24—Record carriers characterised by shape, structure or physical properties, or by the selection of the material
- G11B7/241—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material
- G11B7/252—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of layers other than recording layers
- G11B7/257—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of layers other than recording layers of layers having properties involved in recording or reproduction, e.g. optical interference layers or sensitising layers or dielectric layers, which are protecting the recording layers
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
- G11B7/24—Record carriers characterised by shape, structure or physical properties, or by the selection of the material
- G11B7/241—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material
- G11B7/252—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of layers other than recording layers
- G11B7/257—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of layers other than recording layers of layers having properties involved in recording or reproduction, e.g. optical interference layers or sensitising layers or dielectric layers, which are protecting the recording layers
- G11B7/2578—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of layers other than recording layers of layers having properties involved in recording or reproduction, e.g. optical interference layers or sensitising layers or dielectric layers, which are protecting the recording layers consisting essentially of inorganic materials
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
- G11B7/24—Record carriers characterised by shape, structure or physical properties, or by the selection of the material
- G11B7/26—Apparatus or processes specially adapted for the manufacture of record carriers
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10N—ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10N70/00—Solid-state devices having no potential barriers, and specially adapted for rectifying, amplifying, oscillating or switching
- H10N70/011—Manufacture or treatment of multistable switching devices
- H10N70/021—Formation of switching materials, e.g. deposition of layers
- H10N70/026—Formation of switching materials, e.g. deposition of layers by physical vapor deposition, e.g. sputtering
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10N—ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10N70/00—Solid-state devices having no potential barriers, and specially adapted for rectifying, amplifying, oscillating or switching
- H10N70/20—Multistable switching devices, e.g. memristors
- H10N70/231—Multistable switching devices, e.g. memristors based on solid-state phase change, e.g. between amorphous and crystalline phases, Ovshinsky effect
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10N—ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10N70/00—Solid-state devices having no potential barriers, and specially adapted for rectifying, amplifying, oscillating or switching
- H10N70/801—Constructional details of multistable switching devices
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10N—ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10N70/00—Solid-state devices having no potential barriers, and specially adapted for rectifying, amplifying, oscillating or switching
- H10N70/801—Constructional details of multistable switching devices
- H10N70/821—Device geometry
- H10N70/826—Device geometry adapted for essentially vertical current flow, e.g. sandwich or pillar type devices
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10N—ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10N70/00—Solid-state devices having no potential barriers, and specially adapted for rectifying, amplifying, oscillating or switching
- H10N70/801—Constructional details of multistable switching devices
- H10N70/881—Switching materials
- H10N70/882—Compounds of sulfur, selenium or tellurium, e.g. chalcogenides
- H10N70/8828—Tellurides, e.g. GeSbTe
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
- G11B7/24—Record carriers characterised by shape, structure or physical properties, or by the selection of the material
- G11B7/241—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material
- G11B7/252—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of layers other than recording layers
- G11B7/257—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of layers other than recording layers of layers having properties involved in recording or reproduction, e.g. optical interference layers or sensitising layers or dielectric layers, which are protecting the recording layers
- G11B2007/25705—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of layers other than recording layers of layers having properties involved in recording or reproduction, e.g. optical interference layers or sensitising layers or dielectric layers, which are protecting the recording layers consisting essentially of inorganic materials
- G11B2007/25706—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of layers other than recording layers of layers having properties involved in recording or reproduction, e.g. optical interference layers or sensitising layers or dielectric layers, which are protecting the recording layers consisting essentially of inorganic materials containing transition metal elements (Zn, Fe, Co, Ni, Pt)
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
- G11B7/24—Record carriers characterised by shape, structure or physical properties, or by the selection of the material
- G11B7/241—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material
- G11B7/252—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of layers other than recording layers
- G11B7/257—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of layers other than recording layers of layers having properties involved in recording or reproduction, e.g. optical interference layers or sensitising layers or dielectric layers, which are protecting the recording layers
- G11B2007/25705—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of layers other than recording layers of layers having properties involved in recording or reproduction, e.g. optical interference layers or sensitising layers or dielectric layers, which are protecting the recording layers consisting essentially of inorganic materials
- G11B2007/25715—Record carriers characterised by shape, structure or physical properties, or by the selection of the material characterised by the selection of the material of layers other than recording layers of layers having properties involved in recording or reproduction, e.g. optical interference layers or sensitising layers or dielectric layers, which are protecting the recording layers consisting essentially of inorganic materials containing oxygen
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
- G11B7/004—Recording, reproducing or erasing methods; Read, write or erase circuits therefor
- G11B7/0045—Recording
- G11B7/00454—Recording involving phase-change effects
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
- G11B7/24—Record carriers characterised by shape, structure or physical properties, or by the selection of the material
- G11B7/2403—Layers; Shape, structure or physical properties thereof
- G11B7/24035—Recording layers
- G11B7/24038—Multiple laminated recording layers
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10B—ELECTRONIC MEMORY DEVICES
- H10B63/00—Resistance change memory devices, e.g. resistive RAM [ReRAM] devices
- H10B63/80—Arrangements comprising multiple bistable or multi-stable switching components of the same type on a plane parallel to the substrate, e.g. cross-point arrays
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S430/00—Radiation imagery chemistry: process, composition, or product thereof
- Y10S430/146—Laser beam
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Optical Record Carriers And Manufacture Thereof (AREA)
- Thermal Transfer Or Thermal Recording In General (AREA)
- Manufacturing Optical Record Carriers (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003344944 | 2003-10-02 | ||
JP2003-344994 | 2003-10-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2004216680A1 AU2004216680A1 (en) | 2005-04-21 |
AU2004216680B2 true AU2004216680B2 (en) | 2007-12-13 |
Family
ID=34309147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2004216680A Ceased AU2004216680B2 (en) | 2003-10-02 | 2004-10-01 | Venom-derived vascular endothelial growth factor-like protein having binding activity specific to vascular endothelial growth factor receptor type 2 and use thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US7858290B2 (de) |
EP (1) | EP1521250B1 (de) |
KR (1) | KR100634138B1 (de) |
CN (1) | CN100470646C (de) |
AU (1) | AU2004216680B2 (de) |
DE (1) | DE602004018885D1 (de) |
TW (1) | TW200519928A (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004095034A (ja) * | 2002-08-30 | 2004-03-25 | Pioneer Electronic Corp | 情報記録媒体 |
TW201506922A (zh) * | 2003-07-24 | 2015-02-16 | Panasonic Corp | 資訊記錄媒體及其製造方法 |
JP4468984B2 (ja) * | 2005-04-01 | 2010-05-26 | パナソニック株式会社 | 情報記録媒体とその製造方法 |
JP4593617B2 (ja) * | 2005-06-15 | 2010-12-08 | パナソニック株式会社 | 情報記録媒体とその製造方法 |
WO2007026765A1 (ja) * | 2005-08-30 | 2007-03-08 | Matsushita Electric Industrial Co., Ltd. | 多層情報記録媒体およびその製造方法、並びに多層情報記録媒体の製造装置とこの製造装置を構成する多層情報記録媒体製造用スクリーン |
CN101317225A (zh) * | 2005-11-30 | 2008-12-03 | 松下电器产业株式会社 | 信息记录介质及其制造方法 |
KR20080077969A (ko) * | 2005-12-02 | 2008-08-26 | 마츠시타 덴끼 산교 가부시키가이샤 | 정보 기록 매체와 그 제조 방법 |
JP4542995B2 (ja) * | 2006-02-02 | 2010-09-15 | 株式会社東芝 | 相変化記録媒体 |
US8088464B2 (en) * | 2006-03-31 | 2012-01-03 | Panasonic Corporation | Information recording medium and method for manufacturing same |
KR100856326B1 (ko) * | 2006-07-19 | 2008-09-03 | 삼성전기주식회사 | 레이저 리프트 오프를 이용한 유전체 박막을 갖는 박막 커패시터 내장된 인쇄회로기판 제조방법, 및 이로부터 제조된 박막 커패시터 내장된 인쇄회로기판 |
WO2008018225A1 (fr) * | 2006-08-08 | 2008-02-14 | Panasonic Corporation | Support d'enregistrement d'informations, son procédé de fabrication, et cible de pulvérisation cathodique |
JP2008097802A (ja) * | 2006-09-15 | 2008-04-24 | Tdk Corp | 多層光記録媒体及び多層光記録媒体への記録方法 |
US20080170484A1 (en) * | 2007-01-15 | 2008-07-17 | Tdk Corporation | Optical recording medium |
US7960006B2 (en) * | 2007-01-23 | 2011-06-14 | Tdk Corporation | Optical recording medium and recording film material |
JP4711143B2 (ja) * | 2007-03-19 | 2011-06-29 | Tdk株式会社 | 情報媒体 |
JP5386374B2 (ja) * | 2008-01-31 | 2014-01-15 | パナソニック株式会社 | 光学的情報記録媒体及びその製造方法 |
WO2009096165A1 (ja) * | 2008-01-31 | 2009-08-06 | Panasonic Corporation | 光学的情報記録媒体とその製造方法、及びターゲット |
KR20110055729A (ko) * | 2008-09-12 | 2011-05-25 | 브라이엄 영 유니버시티 | 주입된 산소화 기체를 함유하는 필름 및 이의 제조 방법 |
KR20110061618A (ko) * | 2008-09-12 | 2011-06-09 | 브라이엄 영 유니버시티 | 탄소 및 금속층을 포함하는 데이터 저장 매체 |
JPWO2010041373A1 (ja) * | 2008-10-06 | 2012-03-01 | パナソニック株式会社 | 情報記録媒体とその製造方法、及びスパッタリングターゲット |
JP5398741B2 (ja) * | 2008-12-16 | 2014-01-29 | パナソニック株式会社 | 光学的情報記録媒体及びその記録再生方式 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05159368A (ja) * | 1991-12-03 | 1993-06-25 | Toray Ind Inc | 光記録媒体 |
US6821707B2 (en) | 1996-03-11 | 2004-11-23 | Matsushita Electric Industrial Co., Ltd. | Optical information recording medium, producing method thereof and method of recording/erasing/reproducing information |
JP3612927B2 (ja) | 1997-03-31 | 2005-01-26 | 松下電器産業株式会社 | 光学情報記録媒体 |
US6503690B1 (en) * | 1997-08-12 | 2003-01-07 | Matsushita Electric Industrial Co., Ltd. | Optical information recording medium, method for producing the same, and method for recording and reproducing optical information |
JPH11240252A (ja) * | 1997-12-22 | 1999-09-07 | Tdk Corp | 光記録媒体 |
JP3653390B2 (ja) | 1998-04-07 | 2005-05-25 | 株式会社日立製作所 | 情報記録媒体 |
EP0957477A3 (de) | 1998-05-15 | 2003-11-05 | Matsushita Electric Industrial Co., Ltd. | Optisches Aufzeichnungsmedium, Verfahren und Vorrichtung zur Informationsaufzeichnung und -wiedergabe dafür |
JP3250989B2 (ja) | 1998-05-15 | 2002-01-28 | 松下電器産業株式会社 | 光学情報記録媒体、その記録再生方法、その製造法及び光学情報記録再生装置 |
US6449239B1 (en) * | 1998-11-25 | 2002-09-10 | Matsushita Electric Industrial Co., Ltd. | Optical information recording medium with thermal diffusion layer |
JP3550317B2 (ja) | 1999-05-31 | 2004-08-04 | 京セラ株式会社 | 光記録媒体 |
JP2001067722A (ja) | 1999-08-31 | 2001-03-16 | Kyocera Corp | 光記録媒体 |
US6406771B1 (en) * | 1999-10-29 | 2002-06-18 | Toray Industries, Inc. | Optical recording medium and optical recording apparatus |
JP3913014B2 (ja) | 2000-08-31 | 2007-05-09 | 松下電器産業株式会社 | 情報記録媒体およびその製造方法ならびにその記録再生方法 |
TWI233098B (en) | 2000-08-31 | 2005-05-21 | Matsushita Electric Ind Co Ltd | Data recoding medium, the manufacturing method thereof, and the record reproducing method thereof |
US6761950B2 (en) * | 2001-12-07 | 2004-07-13 | Matsushita Electric Industrial Co., Ltd. | Information recording medium and method for producing the same |
JP2003178487A (ja) * | 2001-12-12 | 2003-06-27 | Hitachi Ltd | 情報記録媒体および製造方法 |
EP1324326B1 (de) | 2001-12-18 | 2005-11-30 | Matsushita Electric Industrial Co., Ltd. | Informationsaufzeichnungsmedium und Verfahren zu dessen Herstellung |
JP2003242683A (ja) * | 2002-02-14 | 2003-08-29 | Hitachi Ltd | 情報記録媒体 |
US6841217B2 (en) | 2002-03-20 | 2005-01-11 | Matsushita Electric Industrial Co., Ltd. | Optical information recording medium and method for manufacturing the same |
JP4181490B2 (ja) * | 2003-03-25 | 2008-11-12 | 松下電器産業株式会社 | 情報記録媒体とその製造方法 |
TW201506922A (zh) | 2003-07-24 | 2015-02-16 | Panasonic Corp | 資訊記錄媒體及其製造方法 |
TW200534235A (en) | 2004-03-10 | 2005-10-16 | Matsushita Electric Ind Co Ltd | Information recording medium and method for manufacturing the same |
-
2004
- 2004-09-29 US US10/953,687 patent/US7858290B2/en not_active Expired - Fee Related
- 2004-09-30 TW TW093129508A patent/TW200519928A/zh unknown
- 2004-10-01 AU AU2004216680A patent/AU2004216680B2/en not_active Ceased
- 2004-10-01 DE DE602004018885T patent/DE602004018885D1/de not_active Expired - Lifetime
- 2004-10-01 EP EP04256080A patent/EP1521250B1/de not_active Expired - Lifetime
- 2004-10-02 KR KR1020040078523A patent/KR100634138B1/ko not_active IP Right Cessation
- 2004-10-08 CN CNB2004100835089A patent/CN100470646C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
TW200519928A (en) | 2005-06-16 |
EP1521250A2 (de) | 2005-04-06 |
EP1521250B1 (de) | 2009-01-07 |
EP1521250A3 (de) | 2006-10-18 |
US20050074694A1 (en) | 2005-04-07 |
KR100634138B1 (ko) | 2006-10-16 |
AU2004216680A1 (en) | 2005-04-21 |
CN100470646C (zh) | 2009-03-18 |
DE602004018885D1 (de) | 2009-02-26 |
CN1604211A (zh) | 2005-04-06 |
KR20050033037A (ko) | 2005-04-08 |
US7858290B2 (en) | 2010-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004216680B2 (en) | Venom-derived vascular endothelial growth factor-like protein having binding activity specific to vascular endothelial growth factor receptor type 2 and use thereof | |
JP6788062B2 (ja) | 抗炎症活性を有するペプチド、及びそれを含む組成物 | |
JP6267190B2 (ja) | 悪液質の予防用または治療用組成物 | |
US9518089B2 (en) | Metallothionein-derived peptide fragments | |
JPH10513049A (ja) | Eph様受容体リガンド | |
JP2004043502A (ja) | 新規蛋白質及びこれを使用した薬剤の製法 | |
HU228068B1 (en) | Protein for blocking platelet adhesion | |
JPH06502538A (ja) | 上皮細胞成長因子(egf)との相同性をもつヘパリン結合性マイトジェン | |
WO1992022320A1 (en) | C1 inhibitor variants and treating inflammatory response with c1 inhibitor | |
EP1574518A2 (de) | VEGF-artiges Protein aus Schlangengift mit spezifischer Bindungsaktivität an VEGF-Rezeptor Typ 2 und dessen Verwendung | |
EP0444149A1 (de) | Hochmolekulare humane angiogenische faktoren | |
KR100703592B1 (ko) | 재조합 혈소판 콜라겐 수용체 당단백질 vi및 이의제약학적 용도 | |
MXPA03003008A (es) | Quimiocinas mutantes en el tratamiento de la esclerosis multiple. | |
RU2186110C2 (ru) | Рекомбинантный белок asp-паллидипин, способ его производства и очистки, вектор, штамм, фармацевтическая композиция | |
US20140088015A1 (en) | Mucin 3 EGF-like Domains | |
WO2023094571A1 (en) | Stabilization of ace2 fusion proteins | |
WO2020239014A1 (zh) | 抗cgrp抗体及其应用 | |
US5188943A (en) | Method of producing high molecular weight human fibroblast growth factors | |
CN103370340B (zh) | 包含dhFas-1结构域和MMP底物的融合肽及其在预防和治疗类风湿性关节炎中的应用 | |
CN101341170A (zh) | 抗白介素-22结合蛋白的抗体及其用途 | |
EP4386084A1 (de) | Verbesserte ace2-fusionsproteine | |
EP4437112A1 (de) | Verbesserte ace2-fusionsproteine | |
JP2007161639A (ja) | 血管内皮増殖因子受容体に対する拮抗的阻害剤としてのヘビ毒由来Lys49−ホスホリパーゼA2の使用 | |
WO2009064051A1 (en) | Novel use of betaig-h3 fragment for preventing and treating rheumatoid | |
Class et al. | Patent application title: Metallothionein-Derived Peptide Fragments Inventors: Vladimir Berezin (Copenhagen N, DK) Vladimir Berezin (Copenhagen N, DK) Elisabeth Bock (Charlottenlund, DK) Milena Penkowa (Copenhagen V, DK) Assignees: UNIVERSITY OF TASMANIA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |